The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients With Advanced Gastrointestinal Stromal Tumors: an Observational Study
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Ripretinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Pharmacokinetics; Therapeutic Use
Most Recent Events
- 26 Feb 2025 Status changed from not yet recruiting to recruiting.
- 31 May 2024 New trial record